...
首页> 外文期刊>Translational Oncology >A Prediction Model Based on Biomarkers and Clinical Characteristics for Detection of Lung Cancer in Pulmonary Nodules
【24h】

A Prediction Model Based on Biomarkers and Clinical Characteristics for Detection of Lung Cancer in Pulmonary Nodules

机译:基于生物标志物和临床特征的肺结节肺癌检测预测模型

获取原文

摘要

Lung cancer early detection by low-dose computed tomography (LDCT) can reduce the mortality. However, LDCT increases the number of indeterminate pulmonary nodules (PNs), whereas 95% of the PNs are ultimately false positives. Modalities for specifically distinguishing between malignant and benign PNs are urgently needed. We previously identified a panel of peripheral blood mononucleated cell (PBMC)-miRNA (miRs-19b-3p and -29b-3p) biomarkers for lung cancer. This study aimed to evaluate efficacy of integrating biomarkers and clinical and radiological characteristics of smokers for differentiating malignant from benign PNs. We analyzed expression of 2 miRNAs (miRs-19b-3p and -29b-3p) in PBMCs of a training set of 137 individuals with PNs. We used multivariate logistic regression analysis to develop a prediction model based on the biomarkers, radiographic features of PNs, and clinical characteristics of smokers for identifying malignant PNs. The performance of the prediction model was validated in a testing set of 111 subjects with PNs. A prediction model comprising the two biomarkers, spiculation of PNs and smoking pack-year, was developed that had 0.91 area under the curve of the receiver operating characteristic for distinguishing malignant from benign PNs. The prediction model yielded higher sensitivity (80.3% vs 72.6%) and specificity (89.4% vs 81.9%) compared with the biomarkers used alone (all P .05). The performance of the prediction model for malignant PNs was confirmed in the validation set. We have for the first time demonstrated that the integration of biomarkers and clinical and radiological characteristics could efficiently identify lung cancer among indeterminate PNs.
机译:通过低剂量计算机断层扫描(LDCT)早期发现肺癌可以降低死亡率。但是,LDCT增加了不确定的肺结节(PNs)的数量,而95%的PNs最终都是假阳性。迫切需要专门区分恶性和良性PN的方法。我们先前确定了一组肺癌外周血单核细胞(PBMC)-miRNA(miRs-19b-3p和-29b-3p)生物标志物。这项研究旨在评估整合生物标志物的有效性以及吸烟者的临床和放射学特征,以区分恶性和良性PN。我们分析了137名患有PN的个体的训练集的PBMC中2个miRNA(miRs-19b-3p和-29b-3p)的表达。我们使用多元logistic回归分析基于生物标志物,PN的放射学特征以及吸烟者的临床特征来开发预测模型,以识别恶性PN。预测模型的性能在111个带有PN的受试者的测试集中得到了验证。建立了一个包含两个生物标记(PNs的针刺和吸烟年数)的预测模型,该模型在接收者操作特征曲线下的面积为0.91,用于区分恶性和良性PNs。与单独使用的生物标志物相比,该预测模型具有更高的敏感性(80.3%对72.6%)和特异性(89.4%对81.9%)(所有P <.05)。在验证集中确认了恶性PN预测模型的性能。我们首次证明,生物标志物与临床和放射学特征的整合可以有效地在不确​​定的PN中识别出肺癌。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号